The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Session highlights: targeting JAK2 and CALR in MPNs
In this video, Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, briefly outlines a session on JAK2 and CALR as promising targets in the treatment of myeloproliferative neoplasms (MPNs). This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Promedior, Incyte, Genetech, Abbvie, Samus, Celgene, Constellation, CTI BioPharma.- a Sobi Company, Mays Cancer Center, NCI;
Consultancy: Constellation, LaJolla Pharma, Sierra Onc, Novartis.
